7
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures [Corrigendum]

      Drug Design, Development and Therapy

      Dove Medical Press

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Mumoli L, Palleria C, Gasparini S, et al. Drug Des Devel Ther. 2015;9:5719–5725. On page 5722, in Table 1, the notes section is missing; it should read: Klein et al34 data presented as percent reduction in seizure frequency over placebo per 28 days. On page 5722, left column, line 8, the sentence “The percent reduction over placebo in baseline-adjusted seizure frequency/28 days was 9.2% and 20.5% in the BRV 50 and 100 mg/d groups, respectively” should read “The percent reduction over placebo in baseline-adjusted seizure frequency/28 days was 10.2%, 9.2% and 20.5% in the BRV 20, 50 and 100 mg/d groups, respectively”. On page 5722, right column, line 9, the sentence “Responder rate was 21.6% for placebo group, 38.9% for BRV 100 mg/d, and 37.8% for BRV 200 mg/d; the percent reduction of partial onset seizures in 28-day frequency was 22.8% for BRV 100 mg and 23.2% for BRV 200 mg” should read “Responder rate was 21.6% for placebo group, 38.9% for BRV 100 mg/d, and 37.8% for BRV 200 mg/d; the percent reduction of partial onset seizures in 28-day frequency over placebo was 22.8% for BRV 100 mg and 23.2% for BRV 200 mg”. On page 5723, left column, line 22, the sentence “Currently an open-label, multicenter, follow-up study to evaluate the long-term safety and efficacy of BRV is ongoing (BRITE study-NCT01339559)” should read “Currently four open-label, multicenter, follow-up studies to evaluate the long-term safety and efficacy of BRV are ongoing: N01125 (NCT00175916), N01199 (NCT00150800), N01372 (NCT01728077), and N01379 - BRITE (NCT01339559)”. On page 5724, the first sentence of the Conclusion should read “BRV is a novel AED whose efficacy in partial epilepsies has been studied and established in six randomized controlled trials;30–35 furthermore, two recent meta-analyses have confirmed significant effects for BRV in patients with refractory partial seizures.29,43” In the reference list, page 5725, reference 34 (Klein et al), the link should be: http://www.abstracts2view.com/aan/view.php?nu=AAN15L1_S31.009, which links directly to the abstract text.

          Related collections

          Author and article information

          Journal
          Drug Des Devel Ther
          Drug Des Devel Ther
          Drug Design, Development and Therapy
          Drug Design, Development and Therapy
          Dove Medical Press
          1177-8881
          2015
          18 December 2015
          : 9
          : 6509
          Article
          dddt-9-6509
          10.2147/DDDT.S101194
          4687622
          © 2015 Mumoli et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License

          The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

          Categories
          Corrigendum

          Pharmacology & Pharmaceutical medicine

          Comments

          Comment on this article